https://www.biopharmadive.com/news/quralis-eli-lilly-als-drug-dementia-deal/717585/
https://www.quralis.com/news/quralis-grants-lilly-exclusive-global-license-for-qrl-204-a-potentially-first-in-class-precision-therapy-that-restores-unc13a-function-in-als-and-ftd/
From what I can gather the ALS drug that Lilly has licensed has only been tested in phase1 and subsequent phases are pending. Based on that PAA has the lead with our ODD & FDA endorsement to conduct a combined phase 2/3 trials. The ODD will also preclude competition for the exclusivity period of 7 years and 7.5 years in the EU if ODD is obtained there.
Monepantel’s modus operandi through autophagy probably is better understood and probably has more applications than QRL-204
AIMO. DYOR.
Pharmaust - Media & News, page-9
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.0¢ |
Change
0.015(6.98%) |
Mkt cap ! $111.9M | |||
| Open | High | Low | Value | Volume |
| 21.5¢ | 23.0¢ | 21.5¢ | $475.3K | 2.128M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 93524 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 71004 | 2 |
View Market Depth
| Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
| PAA (ASX) Chart |